公开(公告)号：US20230233614A1

公开(公告)日：2023-07-27

申请号：US18082907

申请日：2022-12-16

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas Ichim ,  Amit Patel ,  Timothy Warbington

IPC分类号： A61K35/28

CPC分类号： A61K35/28

摘要： The invention provides means, methods, and compositions of matter useful for treatment of viral induced sexual dysfunction. In one embodiment the invention teaches the use of autologous bone marrow mononuclear cells as a source of endothelial repair in penile or clitoral tissues that has been damaged by viral causes. In one embodiment, said viral cause is COVID-19 infection. In some embodiments the invention discloses means of maintaining and/or increasing sexual function, in some cases the invention describes preservation of tissue mass and/or size by administration of regenerative cells. Said cells may be autologous, allogeneic or xenogeneic. In some embodiments the invention teaches the utilization of derivatives of regenerative cells such as exosomes and/or conditioned media.

公开(公告)号：US20230220041A1

公开(公告)日：2023-07-13

申请号：US18082857

申请日：2022-12-16

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas Ichim ,  Amit Patel ,  Timothy Warbington

IPC分类号： C07K14/725 ,  C07K14/54 ,  C07K14/49 ,  C07K14/515 ,  C07K14/65 ,  C07K14/475 ,  C07K16/18 ,  A61K35/17

CPC分类号： C07K14/7051 ,  C07K14/5403 ,  C07K14/49 ,  C07K14/515 ,  C07K14/65 ,  C07K14/4753 ,  C07K16/18 ,  A61K35/17 ,  C07K2319/33 ,  C07K2319/02 ,  C07K2319/03 ,  A61K2039/5156

摘要： A method of creating antigen-specific, chimeric antigen receptor (CAR) T cells capable of secreting regenerative growth factors upon activation of said CAR. In one embodiment said regenerative CAR-T cells possess a CAR capable of selectively recognizing damaged tissue. In one embodiment said CAR recognizes damage-associated molecular patterns (DAMPs) such as ATP, HMGB-1, matricryptins, cold-inducible RNA-binding protein, histones and mitochondrial DNA. Upon activation of said CAR said regenerative CAR-T cell is induced to produce one or more regenerative growth factors. In some embodiments the invention provides a suicide gene in said regenerative CAR-T cells in order to remove said cells after their therapeutic purpose is completed.

公开(公告)号：US20220389385A1

公开(公告)日：2022-12-08

申请号：US17835818

申请日：2022-06-08

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： C12N5/0775 ,  A61P3/10 ,  A61L27/38

摘要： Disclosed are means, methods and compositions of matter useful for prevention and/or reversion of type 1 diabetes by upregulation of myeloid suppressor cell activity in a mammal suffering from and/or at risk of developing type 1 diabetes. In one embodiment the invention teaches administration of immune cells that have been conditioned by exposure to regenerative cells, and/or cultured in the presence of factors produced from regenerative cells. In one embodiment said regenerative cells are umbilical cord derived mesenchymal stem cells. In one embodiment, immune cells that have been exposed to said regenerative cells are administered together with agents known to enhance myeloid suppressor cell activity. In another embodiment immune cells are administered together with exogenous myeloid suppressor cells.

公开(公告)号：US20220226377A1

公开(公告)日：2022-07-21

申请号：US17578298

申请日：2022-01-18

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： A61K35/17 ,  C12N5/0775 ,  C12N5/073 ,  A61K35/28

摘要： Disclosed are methods of ameliorating, inhibition, and/or reversing diabetes utilizing immune cells that have been reprogrammed ex vivo by contact with regenerative cells. In one embodiment said reprogrammed immune cells comprise peripheral blood mononuclear cells obtained from the patient in need of treatment wherein said cells are endowed with properties of immune modulation, and/or suppression of inflammation, and/or restoration of insulin sensitivity, and/or pancreatic regeneration. In one embodiment regenerative cells used for reprogramming are mesenchymal stem cells. In one particular embodiment said cells are umbilical cord derived mesenchymal stem cells. Culture of peripheral blood mononuclear cells together with said regenerative cells is performed in the presence of interleukin-2 and/or an mTOR inhibitor. In one embodiment said mTOR inhibitor comprises rapamycin and/or a derivative thereof.

公开(公告)号：US10792310B2

公开(公告)日：2020-10-06

申请号：US15652213

申请日：2017-07-17

申请人： Creative Medical Technologies, Inc.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： A61K35/44 ,  A61K35/28 ,  A61K31/56 ,  A61K35/22 ,  A61K9/00 ,  C12N5/0775 ,  A61K31/57 ,  A61K31/565 ,  A61K45/06 ,  A61K35/17 ,  C12N5/071 ,  A61K35/51 ,  A61K35/12

摘要： This invention pertains to the field of ovarian aging and premature ovarian failure. Specifically, we herein disclose methods for treating these conditions using endothelial progenitor cells alone or in combination with mesenchymal stem cells. Furthermore, these cell-based therapies can be utilized in combination with estrogen and progesterone receptor ligands to enhance the therapeutic activity of said cells for restoring or maintaining ovarian function and female fertility.

公开(公告)号：US20190022147A1

公开(公告)日：2019-01-24

申请号：US16044256

申请日：2018-07-24

申请人： Creative Medical Technologies, Inc

发明人： Thomas Ichim ,  Amit Patel ,  Santosh Kesari

IPC分类号： A61K35/50 ,  A61P35/00 ,  C12N5/073

摘要： Disclosed are compositions of matter, therapeutic protocols, and cellular reprogramming means to inhibit glioma or other brain neoplasia. In one embodiment the invention provides administration of amniotic fluid derived stem cells at concentrations of 1 million to 200 million administered in a manner to provide a differentiation stimulation, resulting in reduction of malignant potential. In other embodiments, an unexpected synergy of cancer inhibitory soluble factor production is disclosed by combined cultures between amniotic fluid stem cells and monocytes. In all embodiments cells may be autologous or allogeneic. The invention provides means of augmenting efficacy of immunotherapy, chemotherapy, and radiotherapy.

公开(公告)号：US20230218671A1

公开(公告)日：2023-07-13

申请号：US18082841

申请日：2022-12-16

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas Ichim ,  Amit Patel ,  Timothy Warbington

IPC分类号： A61K35/17 ,  A61P43/00

CPC分类号： A61K35/17 ,  A61P43/00

摘要： Disclosed are novel method of inducing tissue regeneration through administration of gamma delta T cells that have been endowed regenerative activity. In one embodiment said regenerative active is bestowed upon said cells by culture with a regenerative cell population. In other embodiments a chimeric antigen receptor (CAR) is transfected which induces generation of regenerative substances upon activation of said CAR. Regenerative factors useful for the treatment of the invention depend on the condition for which treatment is desired, for example, in neurological conditions production of brain derived neurotrophic factor is produced upon activation of said CAR, wherein said CAR recognizes antigens or neoantigens associated with neuronal injury.

公开(公告)号：US20230014637A1

公开(公告)日：2023-01-19

申请号：US17865881

申请日：2022-07-15

申请人： CREATIVE MEDICAL TECHNOLOGIES, INC.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： C12N5/0775

摘要： Disclosed are novel cellular populations generated by explosion of monocytic cells to conditioned media of regenerative cells. In one embodiment said regenerative cells are umbilical cord endothelial cells and said cells are pre-activated to possess enhance ability to reprogram said monocytic lineage cells. In one embodiment monocyte lineage cells are collected from leukopaks by plastic adherence and subsequently cultured in a manner to generate cells similar to M2 cells. In one embodiment said monocytic cells are cultured in a manner to generate myeloid derived suppressor cells. In one embodiment cells are generated to reducing inflammatory conditions. In another embodiment cells are generated for treatment of degenerative conditions. In another embodiment cells are generated for treatment of fibrosis.

公开(公告)号：US20180360882A1

公开(公告)日：2018-12-20

申请号：US16009982

申请日：2018-06-15

申请人： Creative Medical Technologies, Inc.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： A61K35/17 ,  C07K14/71 ,  C12N5/0783 ,  C07K14/435 ,  A61K35/28 ,  A61K9/00 ,  A61K38/19 ,  A61K38/45 ,  A61K38/22

摘要： Disclosed are method of enhancing perispinal perfusion in a patient suffering from reduced perfusion of the lower back through administration of T regulatory cells alone capable of stimulating angiogenesis directly or through enhancement of angiogenic activities of cellular therapies. Said cellular therapies possessing angiogenic activities include mesenchymal stem cells, hematopoietic stem cells and endothelial progenitor cells. In one embodiment of the invention, administration of T regulatory cells is performed that are expanded ex vivo. For certain embodiment of the invention T regulatory cells may be autologous or allogeneic.

公开(公告)号：US20180071342A1

公开(公告)日：2018-03-15

申请号：US15702735

申请日：2017-09-12

申请人： Creative Medical Technologies, Inc.

发明人： Thomas Ichim ,  Amit Patel

IPC分类号： A61K35/50 ,  C12N5/073 ,  C12N5/0775

CPC分类号： A61K35/50 ,  C12N5/0605 ,  C12N5/0668 ,  C12N2510/00

摘要： Disclosed are means of inducing and accelerating neurological recovery subsequent to a stroke through administration of amniotic fluid derived stem cells. In one embodiment stem cells are isolated from amniotic fluid and expanded under conditions allowing for expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4 and CD105. Said cells are subsequently administered into a patient having undergone a stroke, so as to induce direct regeneration (through transdifferentiation and replacement of neural tissue), as well as indirect regeneration (through production of growth factors that augment endogenous regenerative mechanisms while inhibiting degenerative mechanisms). In some embodiments factors produced by said amniotic fluid stem cells may be utilized instead of cells themselves. Said factors may include proteins, peptides, conditioned media, exosomes, or microvesicles.